3 minutes of your time to help us help you

Calling all Longevity investors, founders, c-suite and university spin-outs.

Longevity is hotting-up and we’re asking for 3 minutes of your time to help us help you.

Our 3 minute surveys will provide an understanding the appetite for Longevity investing and the financial needs of Longevity start-ups and scale-ups.

INVESTORS: this survey is for investors of every level; for those that are experienced Longevity investors right through to newbies.

C-SUITE: this survey is for founders, university spin-outs, senior members of management teams and CEOs .

We’ll be sharing the results, of course, and a really big thank you from the Longevity.Technology team.

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

At-home wellness biomarker test to deliver instant results

ZiO Health prepares to launch crowdfunding campaign for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...